MHRA approves dupilumab for treatment of uncontrolled COPD
The regulator has granted marketing authorisation for a subcutaneous injection as an add-on maintenance treatment for adults with uncontrolled COPD.
Dupilumab (Dupixent; Sanofi) reduces type 2 inflammation observed in 30–40% of patients with COPDShutterstock.com
The Medicines and Healthcare products Agency (MHRA) has authorised the use of a new drug for the treatment of uncontrolled COPD.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading
Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading
Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading
Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading
Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Last updated
